GHIJUNG KIM: Open Payments
NPI 1023507100 · SANTA FE, NM. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,783 in 34 payments from 16 companies in 2025. Trend: 2023 $2,544 · 2024 $1,133 · 2025 $1,783
Food & beverage: $1,783
| Company | Payments | Amount |
|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | 10 | $409 |
| AstraZeneca Pharmaceuticals LP | 4 | $229 |
| Novo Nordisk Inc | 2 | $224 |
| Gilead Sciences, Inc. | 1 | $150 |
| Averitas Pharma Inc. | 2 | $150 |
| Boston Scientific Corporation | 1 | $124 |
| Lilly USA, LLC | 1 | $93 |
| Novartis Pharmaceuticals Corporation | 2 | $87 |
| E.R. Squibb & Sons, L.L.C. | 1 | $81 |
| Calliditas Therapeutics US Inc. | 2 | $51 |
Products named: Kerendia, Livdelzi, QUTENZA, LOKELMA, Ozempic, WATCHMAN FLX, FARXIGA, Wegovy.
Industry payments across NM — which companies pay providers there.
